Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties pose risks. See more on PACB stock here.

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...

additional sustained declines in PacBio’s stock price and further changes in the timing of expected future cash flows; and adjustments arising in connection with the preparation and audit of ...

PacBio missed analysts’ revenue expectations ... fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

The Option has an exercise price of $1.33 per share, which is equal to the closing price of PacBio common stock on February 10, 2025 (the “Effective Date”). The shares subject to the Option ...

New York State Common Retirement Fund raised its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – ...

These look promising for the stock. Yet, the continued loss per share reported by PacBio was disappointing. The year-over-year fall in the overall top line and lower Product revenues during the ...